Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
Humacyte (Nasdaq: HUMA), a clinical-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissue at commercial scale, has scheduled its Q4 and full-year 2024 financial results release for March 28, 2025.
The company will host a webcast and conference call at 8:30 a.m. ET on the same day. The webcast will be available 15 minutes before the call begins, and a replay will be accessible on the company's investor relations website for at least 30 days following the broadcast.
Humacyte (Nasdaq: HUMA), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di tessuti umani bioingegnerizzati, impiantabili universalmente e su scala commerciale, ha programmato la pubblicazione dei suoi risultati finanziari del Q4 e dell'intero anno 2024 per il 28 marzo 2025.
L'azienda ospiterà un webcast e una conferenza telefonica alle 8:30 a.m. ET lo stesso giorno. Il webcast sarà disponibile 15 minuti prima dell'inizio della chiamata e una registrazione sarà accessibile sul sito web delle relazioni con gli investitori dell'azienda per almeno 30 giorni dopo la trasmissione.
Humacyte (Nasdaq: HUMA), una empresa de biotecnología en etapa clínica centrada en desarrollar tejidos humanos bioingenierizados que se pueden implantar universalmente a escala comercial, ha programado la publicación de sus resultados financieros del Q4 y del año completo 2024 para el 28 de marzo de 2025.
La empresa llevará a cabo un webcast y una conferencia telefónica a las 8:30 a.m. ET el mismo día. El webcast estará disponible 15 minutos antes de que comience la llamada, y una repetición estará accesible en el sitio web de relaciones con inversores de la empresa durante al menos 30 días después de la transmisión.
Humacyte (Nasdaq: HUMA)는 상업적 규모로 보편적으로 이식 가능한 생체 공학 인간 조직 개발에 중점을 둔 임상 단계의 생명공학 플랫폼 회사로, 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 28일로 예정하고 있습니다.
회사는 같은 날 오전 8:30 ET에 웹캐스트 및 컨퍼런스 콜을 개최할 예정입니다. 웹캐스트는 통화 시작 15분 전에 이용 가능하며, 방송 후 최소 30일 동안 회사의 투자자 관계 웹사이트에서 재생 가능할 것입니다.
Humacyte (Nasdaq: HUMA), une entreprise de biotechnologie en phase clinique axée sur le développement de tissus humains bio-ingénierés, implantables universellement à grande échelle, a programmé la publication de ses résultats financiers du T4 et de l'année complète 2024 pour le 28 mars 2025.
L'entreprise organisera un webcast et une conférence téléphonique à 8h30 ET le même jour. Le webcast sera disponible 15 minutes avant le début de l'appel, et une rediffusion sera accessible sur le site web des relations investisseurs de l'entreprise pendant au moins 30 jours après la diffusion.
Humacyte (Nasdaq: HUMA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von universell implantierbaren, bioengineering menschlichem Gewebe in kommerziellen Maßstab konzentriert, hat die Veröffentlichung seiner Finanzergebnisse für das 4. Quartal und das gesamte Jahr 2024 für den 28. März 2025 angesetzt.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET ein Webcast und eine Telefonkonferenz veranstalten. Der Webcast wird 15 Minuten vor Beginn des Anrufs verfügbar sein, und eine Wiederholung wird für mindestens 30 Tage nach der Übertragung auf der Investor-Relations-Website des Unternehmens zugänglich sein.
- None.
- None.
DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31, 2024, on Friday, March 28, 2025. Management will host a webcast and conference call at 8:30 a.m. ET.
| Title: | Humacyte Fourth Quarter and Full Year 2024 Financial Results and Corporate Update |
| Date: | March 28, 2025 |
| Time: | 8:30 AM Eastern Time |
| Conference Call Details: | 1-877-704-4453 (U.S. Investors Dial) 1-201-389-0920 (International Investors Dial) 13751524 (Conference ID) |
| Call meTM Feature: | Click Here |
| Webcast: | Click Here |
The webcast should be accessible 15 minutes prior to the conference call’s start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Biologics License Application for the acellular tissue engineered vessel (ATEV) in the extremity vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ
When will Humacyte (HUMA) release its Q4 2024 earnings?
What time is Humacyte's (HUMA) Q4 2024 earnings call?
How can investors access Humacyte's (HUMA) Q4 2024 earnings call?
How long will Humacyte's (HUMA) Q4 2024 earnings call replay be available?
